New obesity drug spartina® put to the test in Real-World study

NCT ID NCT07262762

Completed Disease control Sponsor: Cinnagen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study is testing a drug called Spartina® (Tirzepatide) to see how well it helps people with obesity or overweight lose weight and if it is safe. About 175 adults with a BMI of 30 or higher (or 27 with a weight-related health issue) will take the drug. There is no placebo group—everyone gets the active treatment. The main goal is to see how many people lose at least 5% of their body weight.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Akbar Aliasgarzadeh Clinic

Tabriz, East Azerbaijan Province, Iran
Alireza Esteghamati clinic

Tehran, Tehran Province, Iran
Behrang Motamed Clinic

Rasht, Gilan Province, Iran
Dr. Mohammadhossein Dabbaghmanesh Clinic

Shiraz, Fars, Iran
Farzad Hadaegh Clininc

Tehran, Tehran Province, Iran
Hajieh Bibi Shahbazian Clinic

Ahvāz, Iran
Imam Khomeini Hospital

Tehran, Tehran Province, Iran
Iran University Endocrinology Research Center

Tehran, Tehran Province, Iran
Khorshid Clinic

Yazd, Yazd Province, Iran
Mansoor Siavash Dastjerdi Clinic

Isfahan, Isfahan, Iran
Mohammadreza Mohajeri Tehrani Clininc

Tehran, Tehran Province, Iran
Sari Diabetes Research Center

Sari, Mazandaran, Iran
Seyed Mojtaba Mehrdad Clinic

Rasht, Gilan Province, Iran
Shokoofeh Bonakdaran Clininc

Mashhad, Razavi Khorasan Province, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.